- Home
- HRTX
as 12-20-2024 3:37pm EST
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
| Founded: | 1983 | Country: | United States |
| Employees: | 126 | City: | SAN DIEGO |
| Market Cap: | 240.3M | IPO Year: | 1987 |
| Target Price: | $5.67 | AVG Volume (30 days): | 6.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.04 - $3.93 | Next Earning Date: | 11-12-2024 |
| Revenue: | $137,737,000 | Revenue Growth: | 12.13% |
| Revenue Growth (this year): | 13.1% | Revenue Growth (next year): | 18.76% |
Latest Heron Therapeutics Inc. News
HRTX Breaking Stock News: Dive into HRTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 days ago
Exploring Three High Growth Tech Stocks In The United States
MT Newswires
18 days ago
Top Premarket Gainers
MT Newswires
18 days ago
Update: Heron Therapeutics Shares Surge Premarket Following Favorable Cinvanti Patent Ruling
MT Newswires
18 days ago
Heron Therapeutics Shares Surge on Favorable Cinvanti Patent Ruling
PR Newswire
19 days ago
U.S. District Court Upholds Validity of CINVANTI® Patents
GuruFocus.com
a month ago
Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ...
Zacks
a month ago
Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Zacks
a month ago
Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates
Compare HRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRTX Heron Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.